Demicco Elizabeth G
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Semin Diagn Pathol. 2019 Mar;36(2):85-94. doi: 10.1053/j.semdp.2019.02.003. Epub 2019 Feb 28.
Adipocytic neoplasms include a diversity of both benign tumors (lipomas) and malignancies (liposarcomas), and each tumor type is characterized by its own unique molecular alterations driving tumorigenesis. Work over the past 30 years has established the diagnostic utility of several of these characteristic molecular alterations (e.g. MDM2 amplification in well- and dedifferentiated liposarcoma, FUS/EWSR1-DDIT3 gene fusions in myxoid liposarcoma, RB1 loss in spindle cell/pleomorphic lipoma). More recent studies have focused on additional molecular alterations which may have therapeutic or prognostic impact. This review will summarize several of the important molecular findings in adipocytic tumors that have been described over the past 10 years.
脂肪细胞肿瘤包括多种良性肿瘤(脂肪瘤)和恶性肿瘤(脂肪肉瘤),每种肿瘤类型都有其自身独特的驱动肿瘤发生的分子改变。过去30年的研究已经确立了其中几种特征性分子改变的诊断价值(例如,高分化和去分化脂肪肉瘤中的MDM2扩增、黏液样脂肪肉瘤中的FUS/EWSR1-DDIT3基因融合、梭形细胞/多形性脂肪瘤中的RB1缺失)。最近的研究集中在可能具有治疗或预后影响的其他分子改变上。本综述将总结过去10年中描述的脂肪细胞肿瘤的一些重要分子研究结果。